Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia

The present study aimed to apply an electronic, unsupervised patient-reported Expanded Disability Status Scale (ePR-EDSS) to investigate disability severity in people with multiple sclerosis (pwMS) as a case study in Croatia in 2021, including demographic and comorbidity characteristics and multiple sclerosis (MS) disease-related factors. The cross-sectional study was conducted as an online survey from 4 October 2021 to 31 December 2021. Symptom-level disability status was assessed with ePR-EDSS for MS capturing MS-related disability across the spectrum of severity.The study enrolled 147 pwMS patients, of which 84% were women. The mean age ± standard deviation in the sample was 41.1 ± 11.3, and the mean disease duration was 8.5 ± 7.4 years, with a median EDSS score of 3.0 (range, 0–8). The distribution of the participants according to clinical forms of MS was as follows: 71% had relapsing-remitting MS, 13% had primary progressive MS, 4% had secondary progressive PMS, and 12% did not provide information on their MS type. Twenty-nine point two percent (29.2%) of the participants had comorbidities in addition to MS. EDSS scores indicate significant differences with regard to age (t = −3.51, p < 0.001), gender (χ2 = 8.04, p < 0.01), and immunomodulatory drug use (χ2 = 5.89, p < 0.05). An ePR-EDSS analysis of disability symptoms showed a significant difference in symptoms with regard to strength, sensation, coordination, vision, fatigue, mobility, and overall wellness among MS types. Participants with PPMS and SPMS were older on average, had higher EDSS, and had more pronounced symptoms of disability measured with ePR-EDSS compared to those with RRMS. Application of ePR-EDSS shows it to be a reliable eHealth tool for clinical assessment of pwMS disability status, and future studies should correlate it with standard self-report scales capturing MS symptoms such as fatigue, depression, anxiety, and stress.

[1]  J. Cole,et al.  Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments , 2022, Neurology and Therapy.

[2]  M. Rogić Vidaković,et al.  Information Processing Speed Assessed with Letter Digit Substitution Test in Croatian Sample of Multiple Sclerosis Patients , 2022, Diagnostics.

[3]  K. Dolić,et al.  Validation of the fatigue severity scale in Croatian population of patients with multiple sclerosis disease: Factor structure, internal consistency, and correlates. , 2021, Multiple sclerosis and related disorders.

[4]  G. Tedeschi,et al.  Digital therapeutics in neurology , 2021, Journal of Neurology.

[5]  Y. Higueras,et al.  Deciphering Multiple Sclerosis Progression , 2021, Frontiers in Neurology.

[6]  D. Goodin,et al.  The nature of genetic and environmental susceptibility to multiple sclerosis , 2021, PloS one.

[7]  N. Šimić,et al.  Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients. , 2021, Multiple sclerosis and related disorders.

[8]  D. Goodin,et al.  An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis , 2020, Multiple sclerosis.

[9]  C. Russo,et al.  The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis , 2020, European journal of neurology.

[10]  Cassandra E. Meyer,et al.  Sex differences in brain atrophy in multiple sclerosis , 2020, Biology of sex differences.

[11]  J. Kool,et al.  Evaluation of More Stamina, a Mobile App for Fatigue Management in Persons with Multiple Sclerosis: Protocol for a Feasibility, Acceptability, and Usability Study , 2020, JMIR research protocols.

[12]  J. Sellner,et al.  A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications , 2020, Journal of Neurology.

[13]  J. Correale,et al.  Impact of sex hormones on immune function and multiple sclerosis development , 2018, Immunology.

[14]  Y. Valko,et al.  Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients , 2018, Acta neurologica Scandinavica.

[15]  S. Gil-Perotín,et al.  Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies , 2018, Multiple sclerosis journal - experimental, translational and clinical.

[16]  I. Cerovečki,et al.  Prevalence of multiple sclerosis in Croatia: data from national and non-governmental organization registries , 2018, Croatian medical journal.

[17]  S. Bonavita,et al.  Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis. , 2018, Multiple sclerosis and related disorders.

[18]  B. Zeydan,et al.  Progressive Forms of Multiple Sclerosis: Distinct Entity or Age-Dependent Phenomena. , 2018, Neurologic clinics.

[19]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[20]  M. Rensel,et al.  Wellness and the Role of Comorbidities in Multiple Sclerosis , 2017, Neurotherapeutics.

[21]  J. Kamińska,et al.  Multiple sclerosis - etiology and diagnostic potential. , 2017, Postepy higieny i medycyny doswiadczalnej.

[22]  D. Younger,et al.  Epidemiology of Multiple Sclerosis. , 2016, Neurologic clinics.

[23]  D. Goodin,et al.  A comparative analysis of Patient-Reported Expanded Disability Status Scale tools , 2015, Multiple sclerosis.

[24]  Jeffrey A. Cohen,et al.  A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis , 2015, Multiple sclerosis.

[25]  Hanne F. Harbo,et al.  Sex and gender issues in multiple sclerosis , 2013, Therapeutic advances in neurological disorders.

[26]  B. Weinshenker,et al.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis , 2013, Multiple sclerosis.

[27]  Paul C. LaStayo,et al.  Effects of High-Intensity Resistance Training on Strength, Mobility, Balance, and Fatigue in Individuals With Multiple Sclerosis: A Randomized Controlled Trial , 2011, Journal of neurologic physical therapy : JNPT.

[28]  G. Nagels,et al.  Origin of Fatigue in Multiple Sclerosis: Review of the Literature , 2008, Neurorehabilitation and neural repair.

[29]  Ilke Keser,et al.  The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients , 2007, International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation.

[30]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[31]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[32]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[33]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[34]  J. Kurtzke A New Scale for Evaluating Disability in Multiple Sclerosis , 1955, Neurology.

[35]  M. Trojano,et al.  Multiple sclerosis registries in Europe - An updated mapping survey. , 2019, Multiple sclerosis and related disorders.

[36]  B. Çınar,et al.  What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale. , 2018, Noro psikiyatri arsivi.

[37]  R. Bergamaschi Prognostic factors in multiple sclerosis. , 2007, International review of neurobiology.